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Abstract: Flaviviruses including Zika, Dengue and Hepatitis C virus cause debilitating diseases
in humans, and the former are emerging as global health concerns with no antiviral treatments.
We investigated Sophora Flavecens, used in Chinese medicine, as a source for antiviral compounds.
We isolated Sophoraflavenone G and found that it inhibited Hepatitis C replication, but not Sendai or
Vesicular Stomatitis Virus. Pre- and post-infection treatments demonstrated anti-flaviviral activity
against Dengue and Zika virus, via viral RNA polymerase inhibition. These data suggest that
Sophoraflavenone G represents a promising candidate regarding anti-Flaviviridae research.
Keywords: flavivirus; Zika virus; Dengue virus; antiviral; therapy; RNA polymerase

1. Introduction
The Flaviviridae family currently hosts some of the world’s most potentially damaging viruses,
including Hepatitis C (HCV), Yellow fever, West Nile, Japanese encephalitis, Dengue (DENV) and
Zika virus (ZIKV). The diseases caused by these viruses range from chronic liver disease in the
case of HCV [1], hemorrhagic fever and shock syndrome caused by DENV [2], to microcephaly
in newborns during ZIKV infection [3]. The treatment options for these viruses remain severely
limited, with the exception of HCV. Effective Interferon-free antivirals for HCV are available, but at
tremendous financial costs. Despite those treatment options, millions of people remain infected with
HCV worldwide [1]. The treatment for DENV infection, that threatens to infect nearly three billion
people worldwide [2], remains supportive in nature, even in cases of life-threatening hemorrhagic fever,
or shock syndrome. Similarly, there are no antiviral compounds given to ZIKV infected individuals.
This is due in large part to the fact that ZIKV was a relatively neglected arthropod-borne virus and
was considered to cause only mild symptoms until recently [4]. The outbreaks in Oceania and in the
Americas however, were associated with neurological disorders leading to an increase in microcephaly
in fetuses and newborns [5]. It has since been unequivocally demonstrated that ZIKV is found in
neurological tissues and can lead to brain development abnormalities in mice [6,7]. Furthermore,
ZIKV infection was also shown to drive neurological disorders in adults that include Guillain-Barré
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syndrome, meningoencephalitis [8] and myelitis [9]. The discovery of antiviral treatment options to
fight against ZIKV infection is currently underway [10] and one of the top priorities for researchers.
Traditional Chinese medicines include many herbs that have been used to treat a variety of
viral and bacterial infections throughout history. The identification of the compounds and their
mechanisms of action remains an important source for new therapeutics. One such medicinal herb is
Sophora flavescens (SF), whose roots contain many compounds which can be extracted and possess a
broad range of medical applications (reviewed in [11]). Sophora flavescens lectin was recently shown to
decrease tumor mass in vivo, likely through apoptosis induction [12]. Another compound isolated from
SF, oxymatrine, has been used to treat hepatitis infection in China for many years as an inexpensive
alternative to newer treatment options [13]. Modified Kushen Gancao Formula, which is made
with SF, has recently demonstrated anti-cystic fibrosis properties in vivo [14]. In this manuscript,
we investigated if various compounds isolated from SF could be used as anti-Flaviviridae agents and
identified Sophoraflavenone G (SFG) as a potential candidate.
2. Materials and Methods
2.1. Isolation and Identification of Sophoraflavenone G
Air-dried roots of Sophora flavescens were chipped (2.5 kg), and refluxed extracted with EtOH
(KS-E). The solution was collected, the EtOH was removed via evaporation, and the residue was
suspended in salted water (4 L) and extracted with EtOAc (KS-A) or hexane (KS-H). The KS-A extract
was then dried with anhydrous sodium sulfate, filtered and evaporated. 30 g of this was absorbed
onto 27 g of silica gel and subjected to column chromatography (silica gel 230–400 mesh). Successive
elution with a Hexane-Acetone gradient with increasing amounts of Acetone (from 1:1 to 3:4) yielded
10 fractions (KSA-1 to KSA-10). Fraction KSA-2 (3.5 g) was subjected to column chromatography (silica
gel 230–400 mesh, 108 g). Successive elution with Hexane-Acetone (5:4) yielded 9 fractions (KSA-2-1 to
KSA-2-9). Fraction KSA-2-1 (0.9 g) was applied to preparative TLC developed with Hexane-EtOAC
(1:1) and produced KSA-2-1-1, KSA-2-1-2 and KSA-2-1-3 (K211, K212 and K213 respectively).
Following MS, 1 H NMR, 13 C NMR, HMBC and NOESY analysis, the chemical structure of K211
was identified, and the compound was recognized as SFG.
Pure SFG was also obtained from obtained from Wuhan Chemfaces, Wuhan, China.
2.2. Cell Culture
Huh7.5, Huh7.5-20 and IHH cells were cultured in DMEM supplemented with 10% fetal
bovine serum (FBS), 1% penicillin, 1% streptomycin and 1% nonessential amino acids. Primary
human trophoblasts were maintained in RPMI1640 supplemented with 10% FBS and 1% penicillin,
1% streptomycin. A549 (lung carcinoma) were cultured in F12K medium with 10% FBS and 1%
penicillin, 1% streptomycin. All media was obtained from Wisent (Saint Bruno, QC, Canada).
2.3. Virus Production, and Quantification
VSV-GFP (HR strain expressing green fluorescent protein) was propagated on Vero cells and
virus titers were quantified by standard plaque assay on Vero cells. Sendai virus (SeV), obtained from
Charles River Laboratories, was used at 40 HA/mL.
The pJFH1 plasmid, containing full length HCV DNA, was used to generate HCV RNA via
the MEGAscript T7 kit (Ambion, distributed by Thermo Fisher Scientific Inc., Mississauga, ON,
Canada) and purified via RNeasy Kit (Qiagen, Hilden, Germany). The RNA was electroporated
into Huh7.5 cells. After 15 days, the medium was collected and centrifuged at 3,000 rpm for 10 min.
The supernatants were stored at −80 ◦ C, and used at a MOI of 0.1.
DENV2 (DENV serotype 2) (strain New Guinea C) was produced on C6/36 cells and quantified
on Vero cells by flow cytometry as explained below. ZIKV (strain FSS13025) was produced by infecting
Vero cells; the supernatant was collected at 70% cell death, and frozen and thawed 3 times. The lysate
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was centrifuged and then transferred to −80 ◦ C. A549 cells were infected with DENV and ZIKV at
a MOI of 0.5. Trophoblasts were infected with ZIKV at a MOI of 0.1, and SFG was added at the
same time.
2.4. MTT Assay
IHH and A549 cells were plated in triplicate in 96-well flat plates at 1 × 104 cells per
well. 24 h later, cells were treated with SFG. After 24 h, cell viability was measured using
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. A 5 mg/mL MTT stock
solution (Alfa Aesar, distributed by Cedarlane, Burlington, ON, Canada) was added to each well
and incubated for 4 h. The purple MTT formazan crystals were then solubilized with DMSO.
The absorbance was measured at 590 nm wavelength with 620 nm background.
2.5. RNA Dependent RNA Polymerase Activity Assay
The inhibitory effect of SFG on DENV and ZIKV polymerases was evaluated by measuring the
amount of radiolabeled GMP incorporated in newly synthesized RNA (please see the supplementary
methods for details regarding protein expression and purification and references [15,16] for polymerase
validation). This was accomplished by employing homopolymeric poly(rC) as an RNA template/rG13
primer (T/P). Essentially, SFG was tested in a final volume of 60 µL containing; 20 mM Tris-HCl
(pH 6.8), 10 mM NaCl, 0.5 mM TCEP, 0.0005% Igepal-CA630, 5% glycerol, 1 U/µL of SUPERase In
RNase Inhibitor (Thermo Fisher Scientific Inc., Mississauga, ON, Canada), 0.5 µM of T/P poly(rC)/rG13 ,
2.5 mM MnCl2 , 100 µM of cold GTP, 2.5 µCi [3 H]-GTP (~18 Ci/mmol, Perkin Elmer, Waltham, MA,
USA), and 0.2 µM of DENV or ZIKV RdRp. The RdRp reactions were allowed to proceed for 45 min at
30 ◦ C and terminated by the addition of ice-cold 10% cold trichloracetic acid (TCA) and 20 mM sodium
pyrophosphate for 30 min on ice. The precipitated products were filtered onto a 96-well MutiScreen
HTS FC filter plate (EMD Millipore, Etobicoke, ON, Canada). The filter was sequentially washed with
10% TCA twice and 95% ethanol once to remove unincorporated GTP. The radioactivity of incorporated
products was analyzed by a 1450 MicroBeta TriLux Microplate Scintillation and Luminescence Counter
(Perkin Elmer, Waltham, MA, USA).
2.6. DENV and ZIKV E Staining
The percentage of cells infected with DENV or ZIKV was determined by intracellular staining
using a mouse IgG2a mAb, specific for DENV and ZIKV E protein (clone 4G2). In all flow cytometry
experiments, cells were analyzed on a BD LSRII Fortessa Analyzer (San Jose, CA, USA). Calculations,
compensations as well as population analyses were done using BD FACSDiva version 8 software (BD
Biosciences, San Jose, CA, USA).
3. Results
The antiviral potential of several chemical fractions isolated from SF were evaluated for
their ability to prevent HCV replication (Supplementary Figure S1A). Following several rounds
of purification, three lead compounds were isolated from the promising KS-A fraction. The compound
designated K211 inhibited de novo HCV replication to the greatest extent when added pre or post
infection (Supplementary Figure S1B,C). Following structural analyses, the chemical structure of
K211 was identified and recognized as Sophoraflavenone G (SFG) (Figure 1A and Supplementary
Table S1). The addition of this pure compound inhibited HCV replication in a dose dependent manner
in Huh7.5-20 cells that stably produce HCV, at the protein and mRNA level by over 80% (Figure 1B).
The addition of SFG had no effect on two other RNA viruses, Sendai (SeV) and vesicular stomatitis
virus (VSV) (Figure 1C).
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4. Discussion
Here we identified the potent anti-flavivirus properties of SFG. While SFG has been previously
reported to limit bacterial infection [17], to our knowledge, our work is the first to demonstrate
the antiviral properties of SFG. Its deriving plant however, SF, has traditionally been used to treat
hepatitis [18].
The research to uncover antiviral compounds to inhibit DENV and especially ZIKV infection
is underway [10,19]. Although ZIKV was discovered several decades ago [20], it is only now being
carefully studied in the hopes to quickly understand its pathology and identify potential weaknesses
for antiviral therapeutics to exploit. As the virus is carried and transmitted by Aedes aegypti mosquitoes,
which also carry and transmit DENV, it is feared that both ZIKV and DENV endemic regions will grow
and outbreaks will occur more frequently as time passes [21]. ZIKV can also be sexually transmitted,
suggesting that individuals outside of endemic regions may also be at risk [22].
Although within the same family of flaviviridae, HCV and ZIKV/DENV belong to different
genera (Hepacivirus and Flavivirus respectively) which express variations in their RdRP structures,
including an N-terminal extension and an MTase domain [23]. This raises the possibility that the
precise anti-RdRP mechanisms employed by SFG differ between ZIKV/DENV and HCV, if SFG does
target the HCV polymerase at all. Targeting the RdRP is an ideal antiviral strategy, as human cells do
not express them, however we cannot completely rule out that SFG does not interfere with additional
steps of the viral lifecycle. SFG does have anti-cancer and pro-apoptotic properties [24], which may
explain the significant levels of cytotoxicity observed at high doses of SFG. This suggests that further
chemical modifications are required to fully exploit the anti-flaviviral properties of SFG.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1999-4915/9/10/287/s1.
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